Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD
Cassandra Kimber(University of Kansas Medical Center), Jason R. Stubbs(University of Kansas Medical Center), Cassandra Johnson(University of Kansas Medical Center), Bryan Kestenbaum(University of Washington), Andrew N. Hoofnagle(University of Washington), Makoto Miyazaki(Chiba Cancer Center), Thomas D. Nolin(Yamaha (Japan)), Diana Ir(University of Colorado Anschutz Medical Campus), Alan S.L. Yu(University of Kansas Medical Center), Charles E. Robertson(Duke University), Anna Jovanovich(VA Eastern Colorado Health Care System), Daniel N. Frank(University of Colorado Anschutz Medical Campus), Raymond E. West(University of Pittsburgh), Shiqin Zhang(University of Kansas Medical Center), Michel Chonchol(University of Colorado Anschutz Medical Campus), Jonathan D. Mahnken(University of Kansas Medical Center), Alexander J. Prokopienko(University of Pittsburgh)
Cited by 22
Related Papers
Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity
|Science|2013|2k
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
|The Lancet|2010|1.5k
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity
|Proceedings of the National Academy of Sciences|2002|1.1k